- Home
- DHY vs ZVRA Comparison
DHY vs ZVRA Comparison
Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- ZVRA
- Stock Information
- Founded
- DHY 1998
- ZVRA 2006
- Country
- DHY United States
- ZVRA United States
- Employees
- DHY N/A
- ZVRA N/A
- Industry
- DHY Finance/Investors Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- ZVRA Health Care
- Exchange
- DHY Nasdaq
- ZVRA Nasdaq
- Market Cap
- DHY 211.3M
- ZVRA 400.8M
- IPO Year
- DHY N/A
- ZVRA 2015
- Fundamental
- Price
- DHY $2.13
- ZVRA $9.74
- Analyst Decision
- DHY
- ZVRA Strong Buy
- Analyst Count
- DHY 0
- ZVRA 9
- Target Price
- DHY N/A
- ZVRA $22.75
- AVG Volume (30 Days)
- DHY 569.1K
- ZVRA 683.8K
- Earning Date
- DHY 01-01-0001
- ZVRA 08-12-2025
- Dividend Yield
- DHY 9.10%
- ZVRA N/A
- EPS Growth
- DHY N/A
- ZVRA N/A
- EPS
- DHY N/A
- ZVRA N/A
- Revenue
- DHY N/A
- ZVRA $40,588,000.00
- Revenue This Year
- DHY N/A
- ZVRA $292.31
- Revenue Next Year
- DHY N/A
- ZVRA $78.65
- P/E Ratio
- DHY N/A
- ZVRA N/A
- Revenue Growth
- DHY N/A
- ZVRA 46.47
- 52 Week Low
- DHY $1.77
- ZVRA $4.20
- 52 Week High
- DHY $2.08
- ZVRA $10.03
- Technical
- Relative Strength Index (RSI)
- DHY 76.51
- ZVRA 65.74
- Support Level
- DHY $2.12
- ZVRA $8.58
- Resistance Level
- DHY $2.00
- ZVRA $9.43
- Average True Range (ATR)
- DHY 0.02
- ZVRA 0.37
- MACD
- DHY 0.01
- ZVRA -0.00
- Stochastic Oscillator
- DHY 100.00
- ZVRA 80.00
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.